Article info

Download PDFPDF

Original research
Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain

Authors

  1. Correspondence to Dr Bernd Schweikert; Bernd.Schweikert{at}iconplc.com
View Full Text

Citation

Schweikert B, Malmberg C, Núñez M, et al
Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain

Publication history

  • Received July 3, 2019
  • Revised July 2, 2020
  • Accepted July 3, 2020
  • First published August 13, 2020.
Online issue publication 
August 13, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.